Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how hepatotoxicity risks vary among second-line primary biliary cholangitis (PBC) treatments, with seladelpar and elafibranor showing favorable hepatic safety profiles compared to obeticholic acid, though all require regular liver function monitoring and dose adjustments based on individual patient response and disease severity.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

Now Viewing

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

EP: 10.Additional Safety Considerations With PBC Treatments

Video content above is prompted by the following:

Hepatotoxicity is a key safety concern in PBC treatment. How do therapies like seladelpar, elafibranor, and obeticholic acid compare in terms of hepatotoxicity risk, and what monitoring strategies are recommended?